10 likes | 29 Views
DelveInsight's "Opioid-related Disorders - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Opioid-related Disorders, historical and forecasted epidemiology as well as the Opioid-related Disorders market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<br><br>
E N D
1 What is Opioid-related Disorders? Opioid-related Disorders is a chronic disorder that often requires both medication for opioid use disorder (MOUD) and psychosocial treatment and support. Opioid use disorder often requires continuing care to be effective. Effective OUD treatment generally requires pharmacotherapy. There are three FDA-approved medications for treatment of individuals with OUD. Rigorous research has found that MOUDs with an opioid receptor agonist (methadone), partial agonist (buprenorphine), or opioid antagonist (extended-release naltrexone) can facilitate recovery from opioid use disorders. Medication-assisted treatment (MAT) is an effective treatment for individuals with an opioid use disorder. It involves use of medication along with counselling and behavioural therapies. Brain chemistry may contribute to an individual’s mental illness as well as to their treatment. For this reason, medications might be prescribed to help modify one’s brain chemistry. Medications are also used to relieve cravings, relieve withdrawal symptoms and block the euphoric effects of opioids. According to a study titled “Diagnosis and Treatment of Opioid Use Disorder in 2020”, only 6% of addiction treatment facilities offer all 3 medications for OUD management. Medication treatment has been limited by restrictive regulations, such as the Drug Enforcement Administration X waiver requirement for buprenorphine and the requirement that methadone be dispensed in opioid treatment programs. Medical treatment is also limited by segregation of addiction treatment from the medical system, a paucity of addiction treatment programs offering these medications, and stigma. Even when available, pharmacotherapy is often unreasonably restricted through low dosages and limited duration. To improve treatments, it is necessary to improve access and integrate high- quality treatment within medical care